Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration
Top Cited Papers
- 31 July 2006
- journal article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 142 (1), 1-9
- https://doi.org/10.1016/j.ajo.2006.02.037
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Bevacizumab in the treatment of colorectal cancerExpert Opinion on Biological Therapy, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular DegenerationOphthalmology, 2005
- Inhibitors of Ocular NeovascularizationJAMA, 2005
- Pegaptanib for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2004
- Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis, 2004
- Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigenJournal of Molecular Biology, 1999
- Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal AdministrationToxicologic Pathology, 1999
- Polarized Vascular Endothelial Growth Factor Secretion by Human Retinal Pigment Epithelium and Localization of Vascular Endothelial Growth Factor Receptors on the Inner Choriocapillaris: Evidence for a Trophic Paracrine RelationThe American Journal of Pathology, 1999
- 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)Journal of Biological Chemistry, 1998